Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve the prognosis of hormone receptor-positive HER2-negative advanced/metastatic breast cancer (HR+/HER2− mBC). However, some cancers show resistance to CDK4/6i and have a poor prognosis. The non-luminal disease score (NOLUS) was devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Futamura, Manabu, Nakayama, Takahiro, Yoshinami, Tetsuhiro, Oshiro, Chiya, Ishihara, Mikiya, Morita, Midori, Watanabe, Akira, Tanigichi, Azusa, Tsukabe, Masami, Shimoda, Masafumi, Nitta, Kanae, Chihara, Yoko, Yasojima, Hiroyuki, Ouchi, Yoshimi, Tokumaru, Yoshihisa, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587336/
https://www.ncbi.nlm.nih.gov/pubmed/37486454
http://dx.doi.org/10.1007/s12282-023-01485-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587336/
https://www.ncbi.nlm.nih.gov/pubmed/37486454
http://dx.doi.org/10.1007/s12282-023-01485-y

Ejemplares similares